Solve Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $120.0Mattributed |
|---|---|
| Latest round | series-a, $120.0M, 2025-11-19attributed |
| Founded | 2022 |
| Headquarters | San Diego |
| Industry | bio |
| Stage | series-a |
| Website | solvetherapeutics.com |
Solve Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for solid tumors. It serves patients with cancers driven by selectively expressed tumor antigens, with leads SLV-154 and SLV-324 in Phase 1 trials. Its CloakLink hydrophilic linker improves ADC stability and pharmacokinetics.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-11-19 | series-a | $120.0M | undisclosed |
Detected tech stack
Nginx, All in One SEO pro 4.9.1, Google Analytics, Google Tag Manager, Font Awesome, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 3.33.2, DoubleClick Floodlight, Complianz, Vercel Speed Insights, Python
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | solvetherapeutics.com, read 2026-05-07 |
| Description | self-reported | solvetherapeutics.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.